Truist Securities Reiterates Buy on Viking Therapeutics, Maintains $120 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Joon Lee has reiterated a Buy rating on Viking Therapeutics (NASDAQ:VKTX) and maintained a price target of $120.
May 16, 2024 | 1:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities analyst Joon Lee has reiterated a Buy rating on Viking Therapeutics and maintained a price target of $120.
The reiteration of a Buy rating and the maintenance of a high price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100